Appointed
John M. Keane
Director
SIGA ·
SIGA TECHNOLOGIES INC
the Board appointed as a director of the Company General John M. “Jack” Keane (Ret.), effective immediately
Ready 8-Ks
24
Latest filing
May 7, 2026, 7:59 PM ET
Top materiality
0.85
Event mix
earnings ×10 · other_material ×6 · leadership ×5
Sentiment
9 pos · 8 neg · 7 neu
Latest earnings
reported 2026-Q1
Executive change
recent →
Recent 8-K filings for SIGA
Highest-materiality recent filing
SIGA reports Q2 2025 product revenues $79.1M, net income $35.5M, EPS $0.49; new BARDA funding $27M
- Record quarterly total revenue of $195.5M, up 29.4% from $151.1M in Q2 2024, including $79.1M product sales
- Net income of $35.5M ($0.49 diluted EPS) versus $1.8M ($0.03) in Q2 2024; operating income $45.7M vs $1.1M
-
SIGA Q1 net loss widens to $3.5M; revenue falls to $6.2M
Product sales $3.5M vs $5.8M YoY; total revenue $6.2M vs $7.0M.
-
SIGA declares special $0.60/share dividend payable April 23
Special one-time cash dividend of $0.60 per common share declared.
-
SIGA 2025 product revenue $88M, down 34% YoY; net income $23.3M vs $59.2M
Product revenues of $88M in 2025, down from $133M in 2024; total revenues $94.6M.
-
SIGA reports Q3 2025 net loss of $6.4M on $2.6M revenue, down from $1.3M income YoY
Q3 2025 product sales fell to $0.9M from $8.9M YoY; total revenue $2.6M vs $10.0M.
-
SIGA reports Q2 2025 product revenues $79.1M, net income $35.5M, EPS $0.49; new BARDA funding $27M
Record quarterly total revenue of $195.5M, up 29.4% from $151.1M in Q2 2024, including $79.1M product sales
-
All eight director nominees elected; highest vote total 52.1M for John M. Keane; lowest 47.8M for Joseph W. Marshall.
-
SIGA Q1 2025 net loss $0.4M, revenue $7.0M; special dividend $0.60
Q1 2025 total revenues $7.0M (down 72% YoY); net loss $0.4M ($0.01 EPS) vs net income $10.3M ($0.14 EPS) in Q1 2024.
-
SIGA declares special one-time dividend of $0.60/share payable May 15, 2025
Special one-time cash dividend of $0.60 per share declared on April 8, 2025.
-
SIGA Technologies appoints General John M. Keane to Board of Directors
Gen. Keane appointed effective March 17, 2025; term expires at next annual meeting.
-
SIGA FY2024 net income $59.2M ($0.82 EPS); product sales $133M, up 2% YoY
Product sales were $133M in 2024 vs $130.7M in 2023, including $100M to US SNS.
-
SIGA Technologies amends bylaws to update stockholder nomination procedures and proxy rules
Board amended and restated bylaws effective Dec 10, 2024.
-
SIGA's tecovirimat fails mpox lesion resolution endpoint; STOMP enrollment stopped
Tecovirimat did not improve time to lesion resolution vs placebo in mild to moderate clade II mpox; DSMB recommended stop enrollment.
-
SIGA reports Q3 product revenues $8.9M; receives $122M in procurement orders from US government
Product revenues $8.9M (Q3 2024) vs $8.0M YoY; total revenues $10.0M.
-
CFO Luckshire and CSO Hruby target annual bonus drops to 75% of base salary in 2025, then 50% from 2026 onward.
-
SIGA Technologies terminates EVP and CMO Dr. Jay Varma effective immediately
Dr. Jay Varma terminated as EVP and Chief Medical Officer on September 23, 2024.
-
SIGA Technologies CMO and Board Member Jay Varma begins indefinite leave
Dr. Jay K. Varma commenced indefinite leave as EVP, Chief Medical Officer and board member on Sept 19, 2024.
-
SIGA's tecovirimat misses primary endpoint in PALM 007 mpox trial; shows benefit in subgroups
PALM 007 did not meet primary endpoint of statistically significant improvement in time to lesion resolution.
-
SIGA Q2 product sales $20.7M, net income $1.8M; receives $113M U.S. order in July
Product sales $20.7M in Q2 (vs $1.3M prior year); total revenues $21.8M; net income $1.8M or $0.03 diluted EPS.
-
SIGA receives $113M US government procurement order for oral TPOXX
U.S. HHS exercised procurement option for ~$113M of oral TPOXX treatment courses under current contract.
-
SIGA stockholders elect nine directors and ratify PwC as auditor for FY2024
90.04% of shares represented at June 11, 2024 annual meeting.
-
SIGA Q1 2024: product sales $23.9M, net income $10.3M, $0.60 special dividend
Product sales $23.9M vs $5.7M YoY; total revenues $25.4M vs $8.3M.
-
Amendment to Promotion Agreement effective June 1, 2024; SIGA takes over global advertising, promotion and sale of oral TPOXX.
-
Product sales increased 51% YoY to $130.7M (including supportive services) for the year ended Dec 31, 2023.
-
SIGA appoints Diem Nguyen as CEO effective Jan 27, 2024; Phil Gomez retires
Diem Nguyen appointed CEO and board member effective Jan 27, 2024; Phil Gomez retires Jan 26.
Executive changes
Departed
Dr. Jay Varma
Director
SIGA ·
SIGA TECHNOLOGIES INC
Pursuant to the terms of his employment agreement, Dr. Varma’s service on the Company’s Board of Directors also automatically ended effective immediately.
Departed
Dr. Jay Varma
Executive Vice President and Chief Medical Officer
SIGA ·
SIGA TECHNOLOGIES INC
On September 23, 2024, the Board of Directors of SIGA Technologies, Inc. (the “Company”) terminated Dr. Jay Varma, effective immediately, other than for cause, from his position as Executive Vice President and Chief Medical Officer of the Company.
Departed
Jay K. Varma
Executive Vice President and Chief Medical Officer
SIGA ·
SIGA TECHNOLOGIES INC
On September 19, 2024, Dr. Jay K. Varma began an indefinite leave of absence from his positions as Executive Vice President and Chief Medical Officer of SIGA Technologies, Inc. (the “Company”) and as a member of the Board of Directors of the Company.
Departed
Jay K. Varma
Member of the Board of Directors
SIGA ·
SIGA TECHNOLOGIES INC
On September 19, 2024, Dr. Jay K. Varma began an indefinite leave of absence from his positions as Executive Vice President and Chief Medical Officer of SIGA Technologies, Inc. (the “Company”) and as a member of the Board of Directors of the Company.
Appointed
Diem Nguyen
Chief Executive Officer
SIGA ·
SIGA TECHNOLOGIES INC
On January 22, 2024, SIGA Technologies, Inc. (the “Company”) announced the appointment of Diem Nguyen, Ph.D., MBA, as Chief Executive Officer of the Company and a member of the Company’s Board of Directors, in each case, effective as of January 27, 2024
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.70 · Most common event earnings